Table 2.
Baseline demographic characteristics of the study population and enzyme activity in the two groups before the intervention
| Variable | Groups |
P | ||
|---|---|---|---|---|
| Nanocurcumin (n = 35) | Placebo (n = 35) | |||
| Sex | Male | 17 (48.5) | 14 (40.0) | 0.5180 |
| Female | 18 (51.5) | 21 (60.0) | ||
| BMI (kg/m2) | Normal | 3 (8.5) | 5 (14.3) | > 0.9990 |
| Overweight | 26 (74.2) | 25 (71.4) | ||
| Obesity | 6 (17.3) | 5 (14.3) | ||
| Smoking habit | Current | 4 (11.5) | 3 (8.6) | 0.9490 |
| Former | 10 (28.5) | 9 (25.7) | ||
| Never | 21 (60.0) | 23 (65.7) | ||
| Hypertension [n (%)] | Yes | 18 (51.5) | 21 (60.0) | 0.5180 |
| No | 17 (48.5) | 14 (40.0) | ||
| Age (year) | 56.34 ± 11.17 | 60.95 ± 10.77 | 0.1320 | |
| MMP-2 Enzyme activity (pixels) | 18743.80 ± 5785.70 | 17826.20 ± 6597.70 | 0.6220* | |
| MMP-9 Enzyme activity (pixels) | 23102.40 ± 5582.70 | 20353.50 ± 3327.40 | 0.0700* | |
BMI: Body mass index; MMP-2: Matrix metalloproteinase-2; MMP-9: Matrix metalloproteinase-9
Data are presented as Mean ± standard deviation (SD) or n (%).
*
No significant difference existed in the activity of enzymes (MMP-2 and MMP-9) before the intervention between the placebo and curcumin groups.